ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.065
$0.001 (1.52%)
Day Range
$0.065 – $0.067
52 Week Range
$0.052 – $0.155
Volume
20.06K
Avg Volume (10D)
123.61K
Market Cap
$23.96M
Price Chart
Market Statistics
Open$0.065
Previous Close$0.066
Day High$0.067
Day Low$0.065
52 Week High$0.155
52 Week Low$0.052
Valuation
Market Cap23.96M
Shares Outstanding368.68M
Price to Book9.73
Trading Activity
Volume20.06K
Value Traded1.30K
Bid$0.063 × 44,444
Ask$0.068 × 40,000
Performance
1 Day1.54%
5 Day-5.71%
13 Week-7.04%
52 Week8.20%
YTD-37.14%
Technical Indicators
RSI (14)42.42
50-Day SMA$0.073
200-Day SMA$0.092
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.